Table 1.
Characteristics of rheumatoid arthritis patients.
| RA Patients | |
|---|---|
| (n = 1173) | |
| Age, years | 57 ± 12 |
| Female, n (%) | 917 (78) |
| Body mass index, kg/m2 | 28 ± 5 |
| Cardiovascular co-morbidity | |
| Smoking, n (%) | 307 (26) |
| Diabetes, n (%) | 0 (0) |
| Hypertension, n (%) | 285 (24) |
| Dyslipidemia, n (%) | 290 (25) |
| Obesity, n (%) | 327 (28) |
| Statins, n (%) | 252 (21) |
| Laboratory and lipid profile | |
| ESR, mm/1st h | 13 (6–25) |
| CRP, mg/L | 2.6 (0.9–6.3) |
| Cholesterol, mg/dL | 205 ± 36 |
| Triglycerides, mg/dL | 112 ± 63 |
| HDL cholesterol, mg/dL | 61 ± 17 |
| LDL cholesterol, mg/dL | 121 ± 31 |
| Atherogenic index | 3.57 ± 1.06 |
| Rheumatoid arthritis related data | |
| Disease duration, years | 4 (1–10) |
| Age of onset, years | 49 ± 14 |
| DAS28 | 3.05 ± 1.47 |
| DAS28-PCR | 2.81 ± 1.37 |
| SDAI | 10 (5–18) |
| CDAI | 9 (4–16) |
| Rheumatoid factor, n (%) | 694 (59) |
| ACPA, n (%) | 634 (54) |
| Prednisone intake, n (%) | 562 (48) |
| Current prednisone dose *, mg/day | 5 (3–6) |
| NSAIDs intake, n (%) | 471 (40) |
| DMARDs, n (%) | 909 (77) |
| Methotrexate, n (%) | 683 (58) |
| Leflunomide, n (%) | 131 (11) |
| Hydroxychloroquine, n (%) | 254 (22) |
| Anti TNF therapy, n (%) | 158 (13) |
| Abatacept, n (%) | 14 (1) |
| Tocilizumab, n (%) | 59 (5) |
| Rituximab, n (%) | 21 (2) |
| Tofacitinib, n (%) | 11 (1) |
| Baricitinib, n (%) | 9 (1) |
| Carotid assessment | |
| cIMT, microns | 690 ± 140 |
| Carotid plaque, n (%) | 587 (50) |
Data represent means ± SD or median (IQR) when data were not normally distributed; CRP: C reactive protein; LDL: low-density lipoprotein; DMARD: disease-modifying antirheumatic drug; ESR: erythrocyte sedimentation rate; DAS: disease activity score; HDL: high-density lipoprotein; SDAI: Simplified Disease Activity Index; CDAI: Clinical Disease Activity Index; TNF: anti-nuclear tumor factor; ACPA: Anti-citrullinated protein antibody; cIMT, carotid intima media thickness. NSAIDs: Nonsteroidal anti-inflammatory drugs. * In those patients taking prednisone.